ELECTROCOMPETENT CELLS MARKET ANALYSIS

The global electrocompetent cells market size was valued at US$ 2.07 Billion in 2023 and is projected to reach US$ 4.16 Billion by 2030, at a CAGR of 10.5% during the forecast period. The rising demand for electrocompetent cells in the research and development of biopharmaceuticals and vaccines is driving market growth. Electrocompetent cells are used to introduce foreign DNA into bacteria, which can then be used to produce recombinant proteins or other biological products. The increasing use of electrocompetent cells in the research and development of new drugs and vaccines is expected to drive market growth during the forecast period.

Electrocompetent Cells Market Regional Insights

• North America is the leading market for electrocompetent cells, accounting for the largest share of the market in 2023. The market in North America is driven by the presence of a large number of research and development organizations, such as universities, hospitals, and pharmaceutical companies. These organizations are investing heavily in the development of new drugs and vaccines, which is driving the demand for electrocompetent cells. It holds a 35.0% market share.
• The Europe market for electrocompetent cells is the second largest market in the world. The market in Europe is driven by the presence of a large number of research and development organizations, similar to North America. The Europe market is also expected to benefit from the increasing funding for research and development from government agencies. It holds a 25.2% market share.
• The Asia Pacific market for electrocompetent cells is the fastest-growing market in the world. The market in Asia Pacific is driven by the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases. The increasing prevalence of these diseases is driving the demand for new drugs and vaccines, which is driving the demand for electrocompetent cells. It holds a 20.8% market share.

Figure 1. Global Electrocompetent Cells Market Share (%), By Region, 2023

To learn more about this report, request sample copy

Analyst View

The global electrocompetent cells market is poised to witness significant growth over the forecast period, driven by rising demand for plasmids and recombinant DNA for research activities. North America currently dominates the market, aided by robust research funding and presence of leading players. However, Asia Pacific is expected to be the fastest-growing region owing to increasing investments by governments and private organizations in life science research. One of the key opportunities for market participants is the expansion of emerging economies in Asia Pacific and Latin America. These regions offer lower costs for R&D activities, which can attract biopharmaceutical and biotech companies to establish manufacturing and research facilities. However, stringent regulatory frameworks, particularly in the EU, may pose a challenge for new entrants.  Further, the complexity and variability of transforming different bacterial strains efficiently remain major restraints. Significant research efforts are underway to develop improved protocols and more standardized electrocompetent cells with higher transformation efficiencies. Leading players are also focusing on custom product development and value-added services to sustain competition. Collaboration with research institutions is another strategy being adopted to gain improved access to newer technologies. Overall, the rising focus on therapeutics such as gene and cell therapies is expected to boost the sales of electrocompetent cells globally over the next decade. However, in resource-constrained contexts, the high expenses associated with them may limit their use.

Electrocompetent Cells Market Drivers

• Research and Development: Electrocompetent cells are widely used in molecular biology research and biotechnology applications. The continuous advancements in genetic engineering, gene editing technologies (such as CRISPR-Cas9), and synthetic biology have increased the demand for electrocompetent cells. Researchers and scientists rely on these cells to introduce exogenous DNA into cells for various experimental purposes, including gene expression studies, protein production, and drug development.
• Biopharmaceutical Production: The biopharmaceutical industry has witnessed significant growth in recent years. Electrocompetent cells play a crucial role in the production of recombinant proteins, antibodies, and therapeutic enzymes. These cells are used for the expression and amplification of target genes in bioreactors, allowing for large-scale production of biotherapeutics. The increasing demand for biologics and personalized medicines has led to a higher need for electrocompetent cells in biopharmaceutical manufacturing.
• Genetic Engineering and Synthetic Biology: Electrocompetent cells are a fundamental tool in genetic engineering and synthetic biology workflows. They enable the introduction of foreign DNA into host cells, facilitating the creation of genetically modified organisms (GMOs), gene circuits, and metabolic engineering. The growing interest in genetic modification and the development of novel bio-based products drive the demand for electrocompetent cells in this field.
• Academic and Industrial Research: Academic institutions, research laboratories, and industrial R&D centers heavily rely on electrocompetent cells for various studies and experiments. These cells are used in fundamental research to investigate gene functions, protein interactions, and molecular pathways. In both academic and industrial settings, electrocompetent cells are essential for developing new technologies, advancing scientific knowledge, and driving innovation.

Electrocompetent Cells Market Opportunities

• Increasing Adoption of Gene Editing Technologies: The rising adoption of gene editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, provides significant opportunities for the electrocompetent cells market. These technologies require efficient delivery of gene-editing components into target cells, which can be achieved through the use of electrocompetent cells. The demand for electrocompetent cells is projected to rise as gene editing gains traction in research, pharmaceuticals, and agriculture.
• Expansion of Biopharmaceutical Pipeline: The biopharmaceutical industry is witnessing a rapid expansion of its pipeline, driven by advancements in molecular biology and increased understanding of disease mechanisms. Electrocompetent cells play a crucial role in the development and production of biologic drugs, such as monoclonal antibodies, recombinant proteins, and vaccines. As more biopharmaceutical companies invest in research and development of novel therapeutics, the demand for electrocompetent cells is likely to grow.
• Emerging Applications in Agriculture and Food Industry: The application of genetic engineering and synthetic biology in agriculture and food production is gaining traction. Electrocompetent cells can be used to develop genetically modified crops with improved traits, such as enhanced yield, resistance to pests or diseases, and improved nutritional content. Furthermore, electrocompetent cells can facilitate the production of food-grade enzymes, flavors, and other food ingredients through metabolic engineering. As the demand for sustainable and high-quality food products increases, electrocompetent cells offer opportunities in these sectors.
• Advancements in Cell Therapy and Regenerative Medicine: The field of cell therapy and regenerative medicine holds immense promise for treating various diseases and injuries. Electrocompetent cells can be used to engineer stem cells or other cell types with therapeutic potential, enabling their targeted delivery and integration into the patient's body. As the field of regenerative medicine progresses and more cell-based therapies enter clinical trials and commercialization, the demand for electrocompetent cells for cell engineering and manufacturing is expected to rise.

Electrocompetent Cells Market Trends

• Increasing Demand for CRISPR-Cas9 Applications: The adoption of CRISPR-Cas9 technology for gene editing has been rapidly growing across various fields, including biomedical research, therapeutics, and agriculture. This trend has significantly impacted the electrocompetent cells market, as these cells are commonly used for efficient delivery of CRISPR components into target cells. The demand for electrocompetent cells with high transformation efficiency and compatibility with CRISPR-Cas9 systems is on the rise.
• Shift towards Customized Electrocompetent Cells: Researchers often require specialized electrocompetent cells with specific characteristics to suit their experimental needs. This has led to a trend of customization in the electrocompetent cells market, with companies offering tailored solutions. Customization may include optimizing transformation efficiency, improving growth characteristics, or modifying cell strains to meet specific research requirements. The ability to provide customized electrocompetent cells has become a competitive advantage for market players.
• Advancements in Cell-Free Protein Expression: Cell-free protein expression systems, which bypass the need for living cells, are gaining attention due to their flexibility and efficiency. These systems utilize cell extracts containing the necessary cellular machinery for protein synthesis. As a result, there is a growing trend of using electrocompetent cells for the generation of cell extracts to support cell-free protein expression. This trend enables faster protein production and simplifies downstream processing.
• Rising Demand for Animal-Free Recombinant Proteins: The demand for recombinant proteins for research, diagnostics, and therapeutics is increasing. However, concerns regarding animal-derived components in protein production, such as fetal bovine serum (FBS), have prompted a shift towards animal-free alternatives. Electrocompetent cells are being used in the production of animal-free recombinant proteins, reducing the reliance on FBS and ensuring the production of high-quality, animal-free biologics.

Electrocompetent Cells Market Restraints

• Ethical and Regulatory Concerns: The use of genetic engineering technologies, including electrocompetent cells, raises ethical and regulatory concerns. Public perception and ethical debates surrounding genetically modified organisms (GMOs) and gene editing technologies can pose challenges for the market. Stringent regulations and approval processes related to biosafety, bioethics, and environmental concerns can restrict the development and commercialization of certain applications of electrocompetent cells.
• High Development and Manufacturing Costs: The development and manufacturing of electrocompetent cells require sophisticated processes, quality control measures, and specialized equipment. These factors contribute to the high costs associated with electrocompetent cell production. The expenses involved in maintaining sterile conditions, optimizing growth media, and ensuring consistent quality can limit the accessibility of electrocompetent cells, particularly for smaller research laboratories or institutions with limited budgets.
• Limited Transformation Efficiency and Cell Viability: One of the challenges with electrocompetent cells is achieving high transformation efficiency and maintaining cell viability during the transformation process. The efficiency of DNA uptake by cells and subsequent expression can vary depending on the cell type and experimental conditions. Poor transformation efficiency and low cell viability can limit the effectiveness of electrocompetent cells, particularly for applications that require high levels of gene expression or where cell viability is critical.
• Availability of Alternative Technologies: While electrocompetent cells are widely used for gene delivery, there are alternative technologies available for introducing DNA into cells, such as chemical transformation and viral transduction. These alternative methods may offer advantages in specific applications or cell types, and their availability can impact the demand for electrocompetent cells. Researchers may opt for alternative technologies based on factors such as ease of use, efficiency, cost-effectiveness, or compatibility with specific experimental requirements.

Figure 2. Global Electrocompetent Cells Market Share (%), By Application, 2023

To learn more about this report, request sample copy

Recent Developments

New product launches

• In July 2022, Epic-Bio, which is developing ultra-compact therapies to modulate gene expression in vivo, raised US$55 million in Series A funding.
• In June 2022, REGENXBIO INC, a clinical stage biotechnology company opened its new internal facility in the U.S. to produce commercial-scale gene therapies. The company invested US$65 million to enable end-to-end control of gene therapy manufacturing at the center.
• In June 2020, MaxCyte, the global cell-based drug and clinical-stage life sciences company, announced the launch of the first product in its new and expanded line of ExPERT disposables.
• In January 2020, SGI-DNA, a wholly-owned subsidiary of Synthetic Genomics, Inc. (SGI), introduced VmaxTM X2, designed to produce two to four times as much soluble protein in half the time compared to traditional E. coli methods.

Acquisition and partnerships

• In January 2023, MW Group and Solid Power added a research and development license as a basis for their joint next steps. This license enables BMW to build an ASSB prototype line at its Cell Manufacturing Competence Center (CMCC) in Parsdorf, near Munich.
• In October 2022, Takara Bio USA, Inc., a pioneering life science reagents and instrumentation company and a wholly owned subsidiary of Takara Bio Inc., is collaborating with BioExcel Diagnostics, a clinical laboratory to develop and validate a new, comprehensive, high-throughput method for the detection of syndromic diseases.
• In May 2021, New England Biolabs, Inc. (NEB), a leading provider of reagents for the life sciences, announced that it had entered into an agreement to acquire Fluorogenics Limited (FGL), a U.K.-based provider of lyophilization research and development services. Under the terms of the agreement, FGL will become a wholly owned subsidiary of NEB.

Top companies in Electrocompetent Cells Market

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Agilent Technologies, Inc.
• QIAGEN N.V.
• New England Biolabs, Inc.
• GenScript Biotech Corporation
• Lucigen Corporation
• Takara Bio Inc.
• Delphi Genetics S.A.
• IBA GmbH
• Scarab Genomics LLC
• Zymo Research Corporation
• Bioline GmbH (Meridian Bioscience)
• SelectScience
• Biosearch Technology

Definition: The electrocompetent cells market refers to the market for specialized cells that have been treated to become capable of taking up foreign DNA through an electric pulse, enabling genetic engineering and other molecular biology applications. These cells are widely used in research, biotechnology, pharmaceuticals, and other industries for studying gene function, protein expression, genome editing, and producing recombinant proteins. The market encompasses the production, distribution, and sale of electrocompetent cells, along with related products and services.